News headlines about Bioanalytical Systems (NASDAQ:BASI) have trended somewhat positive this week, according to Accern Sentiment. The research group identifies positive and negative news coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Bioanalytical Systems earned a media sentiment score of 0.18 on Accern’s scale. Accern also assigned press coverage about the company an impact score of 45.7035441145854 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.

Shares of Bioanalytical Systems (BASI) traded down 0.63% during mid-day trading on Friday, hitting $1.57. 17,555 shares of the stock traded hands. Bioanalytical Systems has a 1-year low of $0.60 and a 1-year high of $2.42. The company’s 50-day moving average price is $1.77 and its 200 day moving average price is $1.53. The company’s market capitalization is $12.93 million.

Bioanalytical Systems (NASDAQ:BASI) last issued its quarterly earnings results on Monday, August 14th. The company reported $0.03 earnings per share for the quarter. The business had revenue of $5.84 million during the quarter. Bioanalytical Systems had a negative return on equity of 20.72% and a negative net margin of 5.88%. Equities research analysts forecast that Bioanalytical Systems will post $0.01 EPS for the current fiscal year.

WARNING: “Somewhat Favorable Press Coverage Somewhat Unlikely to Affect Bioanalytical Systems (BASI) Stock Price” was first posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this news story on another site, it was stolen and republished in violation of United States and international copyright and trademark legislation. The legal version of this news story can be read at

Bioanalytical Systems Company Profile

Bioanalytical systems, Inc is an international contract research company providing drug discovery and development services and analytical instruments. The Company operates in two segments: contract research services and research products. The contract research services segment provides research and development support on a contract basis to pharmaceutical companies.

Insider Buying and Selling by Quarter for Bioanalytical Systems (NASDAQ:BASI)

Receive News & Stock Ratings for Bioanalytical Systems Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioanalytical Systems Inc. and related stocks with our FREE daily email newsletter.